^
Association details:
| Biomarker: | TMB-L |
|---|---|
| Cancer: | Gastric Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Baseline lesion number as an efficacy predictive and independent prognostic factor and its joint utility with TMB for PD-1 inhibitor treatment in advanced gastric cancer
Published date:
01/31/2021
Excerpt:
The worst efficacy and survival were shown in the BNL-high TMB-low group [ORR: 0% (0/15); DCR: 13.3%; mPFS: 1.7 months; mOS: 2.7 months (all p < 0.05)].
DOI:
10.1177/1758835921988996
